Group 1 - The core point of the article highlights that the U.S. stock market opened slightly lower, with the Nasdaq down 0.09%, the S&P 500 down 0.07%, and the Dow Jones down 0.13% [1] - Novo Nordisk's stock surged over 9% following the FDA approval of its oral Wegovy medication, which is set to launch in January next year [1] - The stock of AmerisourceBergen rose nearly 2% after several major banks raised their target prices, with Wells Fargo increasing its target to $135 [1]

Market Overview - US stock index futures experienced slight declines, with Nasdaq futures down 0.14%, S&P 500 futures down 0.11%, and Dow futures down 0.09% [1] - European stock indices showed mixed results, with Germany's DAX index up 0.05%, UK's FTSE 100 down 0.03%, France's CAC down 0.23%, and the Euro Stoxx 50 down 0.13% [1] Company Developments - Morgan Stanley predicts that if the Federal Reserve lowers interest rates twice next year, the S&P 500 index could reach a target of 7500 points by the end of next year [1] - Apple plans to unveil smart glasses by the end of next year, with official shipments potentially delayed until 2027 [1] - Tesla's sales in Europe fell by 11.8% year-on-year in November to 22,801 vehicles, resulting in a market share decrease to 2.1% [2] - Netflix is refinancing part of a $59 billion bridge loan to support its acquisition of Warner Bros [3] - Oracle founder Larry Ellison will provide over $40 billion in personal guarantees for Paramount's acquisition of Warner Bros [3] - Coinbase is set to acquire the prediction market startup The Clearing Company, with transaction terms undisclosed [4] - Coupang's parent company faces a class-action lawsuit in the US due to a large-scale data breach [4] - New Horizon Capital, in partnership with a US billionaire, is acquiring asset management firm Janus Henderson for approximately $7.4 billion [5] - Strategy has increased its cash reserves to $2.19 billion and has paused Bitcoin purchases over the past week [6] Upcoming Economic Events - Key economic indicators to watch during US trading hours include the initial estimate of Q3 annualized GDP and October durable goods orders at 21:30, November industrial production at 22:15, and December Richmond Fed manufacturing index and consumer confidence index at 23:00 [7]

Group 1: Market Overview - US stock index futures experienced slight declines, with Nasdaq futures down 0.14%, S&P 500 futures down 0.11%, and Dow futures down 0.09% [1] - European stock indices showed mixed results, with Germany's DAX index up 0.05%, UK's FTSE 100 down 0.03%, France's CAC down 0.23%, and the Euro Stoxx 50 down 0.13% [2] Group 2: Corporate Developments - Morgan Stanley predicts that if the Federal Reserve lowers interest rates twice next year, the S&P 500 index could reach a target of 7500 points by the end of next year [4] - Apple plans to unveil smart glasses by the end of next year, with official shipments potentially delayed until 2027 [5] - Tesla's sales in Europe for November fell 11.8% year-over-year to 22,801 units, resulting in a market share decrease to 2.1% [7] - Netflix is refinancing part of a $59 billion bridge loan to support its acquisition of Warner Bros [8] - Oracle founder Larry Ellison will provide over $40 billion in personal guarantees for Paramount's acquisition of Warner Bros [9] - TSMC's Kumamoto factory is reportedly skipping 4nm technology to directly target 2nm in response to AI customer demand [10] - Coinbase is set to acquire the prediction market startup The Clearing Company, with transaction terms undisclosed [11] - Coupang's parent company faces a class-action lawsuit in the US due to a large-scale data breach incident [12] - New Horizon Capital, in partnership with a US billionaire, is set to acquire asset management firm Henderson for approximately $7.4 billion [13] - Strategy has increased its cash reserves to $2.19 billion and has paused Bitcoin purchases over the past week [14]

Core Viewpoint - Danish pharmaceutical giant Novo Nordisk (NVO.US) saw a nearly 10% increase in after-hours trading, reaching $52.79, following the FDA's approval of Wegovy (semaglutide) tablets for oral GLP-1 use in weight management [1] Group 1: Product Approval - Wegovy oral tablets are the first oral GLP-1 receptor agonist approved for weight management [1] - The approval is based on the OASIS and SELECT trial programs [1] Group 2: Clinical Trial Results - In the OASIS 4 trial, a daily dose of 25 mg semaglutide resulted in an average weight loss of 16.6% [1] - The weight loss effect achieved with Wegovy oral tablets is similar to that of the injectable Wegovy at 2.4 mg [1] Group 3: Market Launch - Wegovy oral tablets are expected to be available in the U.S. by early January 2026 [1]